Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Share-based Compensation (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Share-based Compensation for 6 consecutive years, with -$415000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 136.28% year-over-year to -$415000.0, compared with a TTM value of $527000.0 through Sep 2025, down 88.88%, and an annual FY2024 reading of $4.7 million, down 6.84% over the prior year.
  • Share-based Compensation was -$415000.0 for Q3 2025 at Barinthus Biotherapeutics, down from -$281000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $8.7 million in Q2 2021 and bottomed at -$415000.0 in Q3 2025.
  • Average Share-based Compensation over 5 years is $1.9 million, with a median of $1.2 million recorded in 2024.
  • The sharpest move saw Share-based Compensation skyrocketed 2090.91% in 2021, then plummeted 136.28% in 2025.
  • Year by year, Share-based Compensation stood at $3.6 million in 2021, then crashed by 42.99% to $2.0 million in 2022, then tumbled by 61.49% to $786000.0 in 2023, then dropped by 3.94% to $755000.0 in 2024, then tumbled by 154.97% to -$415000.0 in 2025.
  • Business Quant data shows Share-based Compensation for BRNS at -$415000.0 in Q3 2025, -$281000.0 in Q2 2025, and $468000.0 in Q1 2025.